Description: ImCred Patent AB is a consultancy firm specialized on intellectual property matters, and the company was founded 2010 by Ann-Sofie Sternås. Ann-Sofie is an authorized European Patent Attorney and also an authorized attorney before the Swedish Patent Office with over 25 years of IP experience from the pharmaceutical industry, of which almost 20 years as an in-house attorney within “big pharma” and 4 years within an investment company in the life science sector. Ann-Sofie is specialized on IP-strategic and IP-legal matters within the life science area, with a heavy focus on US legislation and the interface between patent law and regulatory law. ImCred Patent can in addition to its own competence, offer a wide international network of top-quality IP lawyers, potential investors and CRO´s.
Description: SGC (founded in 2003) catalyses research in new areas of human biology and drug discovery by focusing explicitly on less well-studied areas of human biology and diseases. SGC accelerates research in these new areas by making all its research output available to the scientific community with no strings attached, and by creating an open collaborative network of scientists in hundreds of universities around the world and in eight global pharmaceutical companies. Michael Sundström, leading the Stockholm based operations, holds the position as Scientific Director for European Initiatives for SGC and is part of the SGC Global Management Team. He is also the Scientific Director for ULTRA-DD, the IMI funded project within this confederation of projects, having around 300 scientists at six different Universities in Brazil, Canada, US, UK, Sweden and Switzerland. www.thesgc.org and www.ultra-dd.org
Description: Ebba Biotech provides innovative staining solutions for biomedical research. Using smart organic chemistry, we develop probes for fluorescence microscopy and spectroscopy. The color of the probe changes dynamically in the presence of specific binding targets, making our products similar to structure-sensitive chameleons. Our first products target neurodegenerative diseases, serving academic research laboratories and clinical institutions worldwide.
EIT Health promotes entrepreneurship and innovates in healthy living and active ageing, with the aim to improve quality of life and healthcare across Europe.
EIT Health is one of the largest healthcare initiatives worldwide. Its goal is to sustainably advance the foundations of healthcare and thus promote the future conditions for healthier living and wellbeing of people across Europe. EIT Health is leveraging the expertise of more than 140 leading organizations spanning key areas of healthcare such as Pharma, MedTech, Payers, Research Institutions and Universities. EIT Health offers best-in-class research capabilities, higher education and business expertise. With a budget of €2 billion over the next decade, it will purposefully invest in Europe’s best entrepreneurial talents and creative minds to foster the development and commercialization of smart product and service solutions in the health sector, addressing the challenges imposed by demographic change and ageing societies. Projects, Education activities and Business Creation activities are financed via in-kind contributions from participating organisations and by funding requested from The EIT. More Information about EIT Health, its members and activities can be found on www.eithealth.eu
Description: The Swedish Gene Technology Advisory Board is a government authority. The Board consists of one politician from each of the political parties in the parliament and seven researchers in areas such as ethics, ecology, cell- and molecular biology and animal genetics. The Board has an office with three employees.
One of the authority´s main tasks is to follow and inform about research and development in the field of gene technology. On the Board’s website there are for example short summaries of current research and the annual report Genteknikens utveckling.
The Board is a consultative body regarding the use of genetically modified organisms, for example marketing approvals for the cultivation of genetically modified crops or clinical trials where genetically modified organisms are used.
Chromafora is a innovation company that offers environmentally benign large scale chemical production processes with significant economical benefits.
The company posses expertise in the field of phosphine chemistry and the use of phosphines attached to solid particles.
Phosphines has known advantages in several chemical transformations, such Wittig, Staudinger, Appel, Mitsunobu. Solid particle synthesis is advantageous primarily due to simplified separation, but also can it enhance conversion and lessen the amount of byproducts.
4 October 2011 the company was also rewarded with SKAPA as “The best Swedish innovation 2011″ given by LAMI and SUF (Svenska Uppfinnar Föreningen).
The company works worldwide to enhance producing companies (customers) production capacity and effectiveness by incorporating the rewarded Chromafora Process.